For instance, inhibitors targeting polo-like kinase 1 (PLK1) can enhance the anti-tumor activity of cisplatin by inducing pyroptosis in esophageal squamous cell carcinoma (31). The gene discussed is PLK1; the disease is esophageal squamous cell carcinoma.